S

Shionogi

Specialty pharma marketing pain and anti-infectives

Head of Rare Diseases

Business & StrategyPosted on Nov 11
Full-timeGermanyNo salary listed

About the Job

Requirements

  • Significant leadership experience in pharma or biotech, including rare disease, orphan medicines or highly specialised care.
  • Proven accountability for a business, franchise, major launch or commercial portfolio, including the transition or integration of an established product or business.
  • Successful launch experience in rare disease, specialty care or another highly concentrated specialist market.
  • Strong experience leading cross-functional teams across Commercial, Medical Affairs and Market Access, and translating strategy into high-quality execution.
  • Strong commercial and financial acumen, including forecasting, investment planning and performance management.
  • Experience building teams, capabilities or new franchises in an evolving environment, and working in complex matrix organisations across local, regional and global teams.
  • Strong understanding of pharmaceutical compliance and the governance of Commercial, Medical Affairs, Market Access and Patient Advocacy.
  • Business-fluent German and English.
  • University degree in life sciences, medicine, pharmacy, health sciences, economics, business or a related discipline.

Responsibilities

  • Build and lead the DACH rare-disease business and own the integrated business and brand plan across current and future assets.
  • Own the DACH rare-disease profit and loss, including forecasting, investment and gross-to-net, and build business cases for capabilities, headcount and investments.
  • Lead launch readiness and commercialisation for the first rare-disease treatment, developing a launch sequence and roadmap for Germany, Austria and Switzerland with governance, milestones and readiness indicators.
  • Plan lifecycle and franchise development for future indications, subject to regulatory approval.
  • Lead the seamless transition of an established Swiss rare-disease business to Shionogi, protecting uninterrupted patient access and supply.
  • Maintain relationships with specialist centres, physicians and patient organisations, deliver a focused growth strategy, integrate the Swiss business into the DACH franchise and build scalable Swiss capabilities.
  • Shorten the path from awareness and diagnosis to specialist referral and treatment; build partnerships with expert centres, networks and diagnostic laboratories, and establish a centre-centric account model.
  • Set the DACH access ambition and lead country-specific strategies, including preparation for AMNOG and the Austrian and Swiss pathways.
  • Anticipate reimbursement, pricing and evidence risks, and work with Medical Affairs on evidence planning.
  • Ensure patient and caregiver perspectives shape strategy; build transparent relationships with patient organisations and create a credible rare-disease presence in DACH with Communications and Corporate Affairs.
  • Build, recruit and lead a lean, high-performing cross-functional team with simple operating mechanisms, respecting the independence of Medical Affairs, Regulatory, Pharmacovigilance and Compliance while remaining accountable for the integrated business outcome.
  • Align Patient Services, Supply, Quality, Regulatory and other partners around launch needs; plan for supply continuity and, where permitted, continuity-of-access or early-access mechanisms under appropriate governance.

Desired Qualifications

  • An advanced scientific or business qualification.
  • Experience with ultra-rare diseases, lysosomal storage disorders, or neurometabolic, neurogenetic and rare neurological diseases.
  • Experience with centre-based rare-disease commercial models, patient identification and diagnostic-pathway initiatives.
  • Experience with German AMNOG and DACH pricing and reimbursement, patient advocacy and expert-centre networks.
  • Experience with multi-country DACH responsibility and launches requiring new organisational infrastructure.
  • Experience with business transfer, post-merger integration or marketing-authorisation transfer.
  • Experience in small or mid-sized biotech environments and entrepreneurial build-up situations.

About the Company

Shionogi

Specialty pharma marketing pain and anti-infectives

Shionogi expanded its U.S. portfolio by acquiring Victory Pharma’s marketed products, adding pain medications and anti-infectives to its lineup. The products include Naprelan for pain and anti-infectives like MOXATAG and KEFLEX, which Shionogi’s existing U.S. sales force markets to doctors. The move paired a pain-focused line with infectious-disease drugs to balance seasonal demand and reach pain specialists, rheumatologists, orthopedic surgeons, and some primary care physicians. The goal was to grow Shionogi’s presence in U.S. pain management and infectious diseases by integrating Victory Pharma’s products into its sales and marketing engine, though Victory Pharma later faced a federal settlement related to promotional practices.

Company size
501-1,000
Company stage
IPO
Headquarters
Florham Park, NJ
Founded
2001

Recently Posted Jobs

Explore more opportunities at Shionogi

See more jobs